About Us
Shunfeng Pharmaceutical Packaging Materials Co., Ltd. is located in Shunde, the renowned home of home appliances and cuisine in China. Founded in May 2000, the company is a pharmaceutical packaging materials manufacturer deeply rooted in the niche of pharmaceutical aluminum tubes and dedicated to serving large pharmaceutical enterprises. It has been awarded Grade-A supplier qualifications by multiple group pharmaceutical companies and has helped numerous formulations pass consistency evaluation.
The company has been recognized as a National High-Tech Enterprise, a Science and Technology SME, and a Clean Production Enterprise, with solid R&D and innovation capabilities and more than 60 national patents. Relying on mature intelligent production lines and AI in-line quality control technology, its current designed annual capacity is 600 million tubes. With completed environmental impact assessment and official approval, the capacity keeps upgrading and can fully meet the core commercial needs of pharmaceutical companies: compliant customization, rapid mass production and stable delivery. Products cover the full range of mainstream specifications from Φ11mm to Φ35mm, fully adapting to topical formulation packaging scenarios of different dosage forms and capacities, with complete specifications, strong adaptability and outstanding supporting capabilities.
The company's products are compatible with nearly one hundred mainstream topical formulations, fully covering core pharmaceutical segments such as skin antibiosis, ophthalmic sterility, and analgesia & repair, including classic preparations such as compound dexamethasone acetate, ketoconazole, erythromycin, compound Beijia ointment (Wuji cream), fusidic acid, desonide, mupirocin, mometasone furoate, halometasone, halometasone-triclosan, tretinoin, metronidazole, lidocaine-lignocaine, calcipotriol, naftifine-ketoconazole, pimecrolimus, compound flumetasone, benvitimod, bifonazole, etofenamate, clioquinol, chlortetracycline hydrochloride, compound lidocaine, fluticasone propionate, hydrocortisone butyrate, clotrimazole, trimix (triamcinolone-neomycin-cymrinol), salicylic acid, halcinonide, penciclovir, clobetasone butyrate, tazarotene-betamethasone, doxepin hydrochloride, luliconazole, urea cream, beclomethasone dipropionate, fluocinonide acetate, triamcinolone acetonide-econazole acetate, methylprednisolone aceponate, betamethasone valerate, fluocinonide-hydroquinone-tretinoin, hydrocortisone, crotamiton, acyclovir, frostbite ointment, miconazole nitrate, snake-fat ointment, dermatitis cream, diclofenac sodium, chlorhexidine gluconate, and neomycin-fluocinonide. Validated extensively in the market terminal, the products have proven safety, stability and compatibility, wide application scenarios and strong commercialization capability.
Aligning with new industry regulations and industrial upgrading trends, the company strictly benchmarks against the 2025 edition of the Chinese Pharmacopoeia guidelines for pharmaceutical packaging materials and the GMP Annex for Pharmaceutical Packaging Materials effective in 2026, fully complying with the new pharmacopoeia "1+4+58" system, and continuously upgrades capacity, production processes and quality control technologies. Adhering to the three core competitiveness of compliance, scale and stability, the company continues to safeguard formulation enterprises in project R&D, registration and commercialization, supporting the high-quality development of the pharmaceutical and health industry.
